sncRNA levels predict SNORD105B is a novel biomarker of chronic kidney disease risk and SGLT2 inhibitor response in type 2 diabetes
Rattachement africain : nl. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Chronic kidney disease (CKD) is a common complication of type 2 diabetes, characterized by reduced kidney function and/or albuminuria, yet its progression varies widely among individuals. While sodium-glucose cotransporter-2 (SGLT2) inhibitors are known to protect against kidney decline, the molecular mechanisms underlying their renoprotective effects remain incompletely understood. Circulating small non-coding RNAs (sncRNAs), particularly microRNAs, have been linked to CKD but the contribution of other sncRNA classes is less explored. We profiled plasma sncRNAs in 263 participants with type 2 diabetes from the Hoorn DCS cohort without CKD at baseline, followed for ∼9 years ( n control = 122, n case = 141). sncRNA profiling was also performed before and after treatment of SGLT2 inhibitors in three trials ( n = 65, total) to assess drug-induced molecular changes in the circulation. Eleven sncRNAs were nominally associated with incident CKD, most strongly SNORD12C and SNORD105B . In an independent SGLT2 inhibitor trial, exploratory analyses identified 34 sncRNAs that changed following treatment, including SNORD105B . Preliminary analyses linked these snoRNAs to co-regulated proteins, suggesting potential functional relevance. Our results identify snoRNAs, particularly SNORD105B , as potential novel markers of CKD risk and SGLT2 inhibitor response in type 2 diabetes, revealing an unexplored sncRNA axis and providing a foundation for future functional studies into their mechanistic role in CKD progression.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- sncRNA levels predict SNORD105B is a novel biomarker of chronic kidney disease risk and SGLT2 inhibitor response in type 2 diabetes
- Date Crossref
- 01/06/2026
- Éditeur
- Elsevier BV
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Leiden University Medical Center Department of Cell and Chemical Biology pays non établi dans la noticeOrganisme public
-
Public Health Service of Amsterdam pays non établi dans la noticeÉtablissement de santé
-
Vrije Universiteit Amsterdam pays non établi dans la noticeUniversité ou école supérieure
-
University Medical Center Utrecht Julius Center for Health Sciences and Primary Care pays non établi dans la noticeÉtablissement de santé
-
Amsterdam Public Health Department of General Practice and Elderly Care Medicine pays non établi dans la noticeStructure de recherche
-
Amsterdam University Medical Centers Department of Internal Medicine pays non établi dans la noticeÉtablissement de santé
-
Location Vrije Universiteit Department of Epidemiology and Data Science pays non établi dans la noticeUniversité ou école supérieure
Department of Cell and Chemical Biology — Leiden University Medical Center, Public Health Service of Amsterdam et Vrije Universiteit Amsterdam, avec 4 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.